

FORM PTO-1350 (Modified)  
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

217926US0PCT

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

**10/031339**

INTERNATIONAL APPLICATION NO.  
**PCT/GB00/02788**

INTERNATIONAL FILING DATE  
**19 July 2000**

PRIORITY DATE CLAIMED  
**21 July 1999**

TITLE OF INVENTION  
**NEW USE OF A MACROLIDE COMPOUND**

APPLICANT(S) FOR DO/EO/US  
**JONES Paul Alexander et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (e)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

**Items 13 to 20 below concern document(s) or information included:**

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

**Request for Consideration of Documents Cited in International Search Report  
PCT/IB/308/Notice of Priority**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.107) <b>107031339</b>		INTERNATIONAL APPLICATION NO. <b>PCT/GB00/02788</b>		ATTORNEY'S DOCKET NUMBER <b>217926US0PCT</b>	
--	--	---	--	---	--

24. The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</b> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1040.00</b> <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$890.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$740.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$710.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>				<b>CALCULATIONS PTO USE ONLY</b>	
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$890.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (c)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30				<b>\$130.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	6 - 20 =	0	x \$18.00	<b>\$0.00</b>	
Independent claims	3 - 3 =	0	x \$84.00	<b>\$0.00</b>	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$1,020.00</b>	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				<b>\$0.00</b>	
<b>SUBTOTAL =</b>				<b>\$1,020.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (i)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$1,020.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$1,020.00</b>	
				Amount to be refunded	\$
				charged	\$

a. ☒ A check in the amount of **\$1,020.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **15-0030**. A duplicate copy of this sheet is enclosed.


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**Surinder Sachar**  
**Registration No. 34,423**

  
**22850**

  
 SIGNATURE  
**Norman F. Oblon**  
 NAME  
**24,618**  
 REGISTRATION NUMBER  
**Jan 18 2002**  
 DATE

10/031339

NEW USE OF A MACROLIDE COMPOUND

## TECHNICAL FIELD

This invention relates to a new use of a macrolide compound.

## BACKGROUND ART

A certain macrolide compound, i.e., tacrolimus, and its related compounds are known to have preventing or treating activity of cerebral infarction (USP 5,648,351). However, it is desirable to provide more effective and/or safer drug with a superior pharmaceutical profile against cerebral ischemic disease.

## DISCLOSURE OF INVENTION


The inventors of this invention have found that one of the tacrolimus analogues, i.e., a compound (I), mentioned below, has an excellent neuroprotective efficacy.

Accordingly, this invention provides a new use of the compound (I) as a neuroprotective agent.

Further, this invention provides a neuroprotective agent, which comprises the compound (I).

Still further, this invention provides a method for preventing or treating acute or chronic cerebral neurodegenerative diseases, which comprises administering said compound (I) to mammals.

The tacrolimus analogue used in the present invention has the following chemical formula.



It has already been produced in USP 5,376,663, example 29.

With respect to the compound (I) used in the present invention, it is to be understood that there may be conformers and one or more stereoisomers such as optical and geometrical isomers due to asymmetric carbon atom(s) or double bond(s), and such conformers and isomers are also included within the scope of the compound in the present invention. And further, the compound can be in the form of a solvate or pro-drug, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate.

The compound (I) usable in the present invention may be administered as pure compound or mixture of compound or

preferably, in a pharmaceutical vehicle or carrier.

The compound (I) in this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the compound(I), as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external(topical), enteral, intravenous, intramuscular, or parenteral applications. The active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable, carriers for tablets, pellets, capsules, eye drops, suppositories, solutions (saline, for example), emulsion, suspensions (olive oil, for example), ointment, aerosol sprays, cream, skin plasters, patches and any other form suitable for use. The carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The active object compound is included in the pharmaceutical composition in an effective amount sufficient to produce the desired effect upon the process or condition of the disease.

Mammals which may be treated using the method of the

present invention include livestock mammals such as cows, horses, etc., domestic animals such as dogs, cats, rats, etc. and humans.

For applying this composition to a human, it is preferable to apply it by injection.

While the dosage of therapeutically effective amount of the macrolide compounds varies from and also depends upon the age and condition of each individual patient to be treated, a daily dose of about 0.0001-1000 mg, preferably 0.001-500 mg and more preferably 0.01-100 mg. of the active ingredient is generally given for treating diseases, and an average single dose of about 0.001-0.01mg, 0.2-0.5 mg, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg, 250 mg and 500 mg is generally administered. Daily doses for chronic administration in humans will be in the range of about 0.1-30 mg/kg/day.

And further, the compound (I) can be applied, simultaneously, separately or sequentially, with other agents having neuroprotective activity, such as thrombolytics (e.g., tPA, urokinase, etc), fibrinolytics, platelet inhibitors and so on.

The following examples illustrate the present invention in further detail. It should be understood that those examples are not intended to limit the scope of the invention.

#### Example 1

Neuroprotective efficacy of the compound (I) in the rat

endothelin-induced MCA occlusion model

(1) METHOD

The compound (I) was dissolved in a polyoxyethylene-hydrogenated castor oil 60/ethanol (400mg/ml) solution and administered at 1 and 3 mg.kg<sup>-1</sup>. All drugs and relevant control were administered in a volume of 2 ml.kg<sup>-1</sup>. MCA occlusion by the endothelin method was performed on male Sprague Dawley rats (271 - 324g) as described in USP 5,648,351. All drugs were infused through the i.v. catheter at 1 ml min<sup>-1</sup>, five minutes post-lesion. The animals were sacrificed by cardiac infusion under barbiturate anaesthesia. Volume of lesion was calculated from measured areas of damage (as assessed three days post-lesion) using the Trapezoid Rule. Results are presented as volume (mm<sup>3</sup>)  $\pm$  SEM. Statistical analysis was performed using ANOVA and post hoc Student-Newman-Keuls test, where  $p < 0.05$  was set as an acceptable level for significance.

(2) RESULT

Protection in the ET-1 model of stroke by the compound (I) at 1 mg.kg<sup>-1</sup> (n=14) and 3 mg.kg<sup>-1</sup> (n=9) against vehicle (n=11) was studied. The compound (I) protected the cortex 61% and 42% respectively at both 1 and 3 mg.kg<sup>-1</sup>.

The compound (I) was proved to have a neuroprotective

efficacy, though it has no immunosuppressive activity. So, the present invention provides useful neuroprotective agent for preventing or treating acute or chronic cerebral neurodegenerative diseases, such as brain damage caused by ischemia or hemorrhage, etc.


So, it is useful when the following diseases or injury occur; that is, cerebral infarction, hemorrhage infarct, multi-infarct dementia, head injury, hemorrhage in brain such as subarachnoid hemorrhage or intracerebral hemorrhage, cerebral thrombosis, cerebral embolism, cardiac arrest, stroke (such as, acute, subacute, or chronic stroke), transient ischemic attacks (TIA), hypertensive encephalopathy, etc.

The patents, patent applications and publications cited herein are incorporated by reference.



CLAIMS

1. A use of a compound of the following formula:



for manufacturing a neuroprotective agent.

2. A method for preventing or treating acute or chronic cerebral neurodegenerative diseases, which comprises administering the compound (I) identified in Claim 1 to mammals.
3. A pharmaceutical composition for preventing or treating acute or chronic cerebral neurodegenerative diseases, which comprises compound (I) in admixture with a carrier or excipient.
4. The composition in Claim 3, in which the cerebral neurodegenerative diseases is brain damage caused by ischemia or hemorrhage.
5. The composition in Claim 4, in which the cerebral neurodegenerative diseases is cerebral infarction.

6. A use of the compound (I) for preventing or treating acute or chronic cerebral neurodegenerative diseases.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
25 January 2001 (25.01.2001)

PCT

(10) International Publication Number  
**WO 01/05385 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/00**
- (21) International Application Number: **PCT/GB00/02788**
- (22) International Filing Date: **19 July 2000 (19.07.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
9917158.9                      21 July 1999 (21.07.1999)    **GB**
- (71) Applicant (for all designated States except US): **FUJISAWA PHARMACEUTICAL CO LTD [JP/IP];**  
4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka  
541-8514 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **JONES, Paul, Alexander [GB/GB];** University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ (GB). **SHARKEY, John [GB/GB];** University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ (GB). **KELLY, John, Shearer [GB/GB];** University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ (GB).
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**
- (74) Agents: **GAUNT, Robert, John et al.;** Stevens Hewlett & Perkins, Halton House, 20/23 Holborn, London, Greater London EC1N 2JD (GB).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **NEW USE OF A MACROLIDE COMPOUND**(57) Abstract: **Macrolide compound, such as a tacrolimus analogue is provided for use as a neuroprotective agent, particularly, for preventing or treating acute or chronic cerebral neurodegenerative diseases.****WO 01/05385 A2**

## Declaration and Power of Attorney For Patent Application

## 特許出願宣言書及び委任状

## Japanese Language Declaration

## 日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

私の住所、郵便の宛先、国籍は下記の私の氏名の後に記載された通りです。

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者（下記の名称が複数の場合）であると信じています。

上記発明の明細書は、

☐ 本書に添付されています。

☐ \_\_\_\_ 月 \_\_\_\_ 日に提出され、米国出願番号または特許協定条約国際出願番号を

\_\_\_\_ とし、

(該当する場合) \_\_\_\_ に訂正されました。

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

As a below named inventor, I hereby declare that:

My residence, mailing address and citizenship are as stated next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.

## NEW USE OF A MACROLIDE COMPOUND

the specification of which

☐ is attached hereto.

☒ was filed on July 19, 2000

as United States Application Number or PCT International Application Number

PCT/GB00/02788 and was amended on

\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

# Japanese Language Declaration (日本語宣言書)

10031339.051702

私は、米国法典第35編119条(a) - (d)項又は365条 (b) 項に基づき下記の、米国以外の国の少なくとも一カ国を指定している特許協力条約365(a)項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)  
外国での先行出願

9917158.9 ✓  
(Number)  
(番号)

Great Britain ✓  
(Country)  
(国名)

私は、第35編米国法典119条 (e) 項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条 (c) に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

PCT/GB00/02788  
(Application No.)  
(出願番号)

July 19, 2000  
(Filing Date)  
(出願日)

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じていることに基づき表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。  
委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。  
(弁理士、または代理人の指名及び登録番号を明記のこと)

I hereby claim foreign priority under Title 35, United States Code, § 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Priority Claimed  
優先権主張

21 July 1999 ✓  
(Day/Month/Year Filed)  
(出願年月日)

☒ Yes  
はい

☐ No  
いいえ

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application No.)  
(出願番号)

(Filing Date)  
(出願日)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

(Status: Patented, Pending, Abandoned)  
(現況：特許許可済、係属中、放棄済)

(Status: Patented, Pending, Abandoned)  
(現況：特許許可済、係属中、放棄済)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: (list name and registration number)

# Japanese Language Declaration

(日本語宣言書)



022850

書類送付先

Send Correspondence to:





022850


直接電話連絡先：(名前及び電話番号)

Direct Telephone calls to: (name and telephone number)

(703) 413-3000

単独発明者または第一の共同発明者の氏名	1-00	Full name of sole or first inventor <u>Paul Alexander Jones</u>
発明者の署名	日付	<input checked="" type="checkbox"/> Inventor's signature  <input checked="" type="checkbox"/> Date <u>12th April, 2002</u>
住所		Residence University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, Great Britain <u>GBX</u>
国籍		Citizenship Great Britain <input checked="" type="checkbox"/>
郵便の宛先		Mailing Address Same as Above

第二の共同発明者の氏名	2-00	Full name of second joint inventor, if any <u>John Sharkey</u>
第二の共同発明者の署名	日付	<input checked="" type="checkbox"/> Second inventor's signature  <input checked="" type="checkbox"/> Date <u>9th April 02</u>
住所		Residence University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, Great Britain <u>GBX</u>
国籍		Citizenship Great Britain <input checked="" type="checkbox"/>
郵便の宛先		Mailing Address Same as Above

第三の共同発明者の氏名	3-00	Full name of third joint inventor, if any <u>John Shearer Kelly</u>
第三の共同発明者の署名	日付	<input checked="" type="checkbox"/> Third inventor's signature  <input checked="" type="checkbox"/> Date <u>11th April 02</u>
住所		Residence University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, Great Britain <u>GBX</u>
住所		Citizenship Great Britain <input checked="" type="checkbox"/>
郵便の宛先		Mailing Address Same as Above